• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Gen Intern Med . Is Lockdown Effective in Limiting SARS-CoV-2 Epidemic Progression?-a Cross-Country Comparative Evaluation Using Epidemiokinetic

tetano

Editor, Senior Moderator
J Gen Intern Med


. 2021 Jan 13.
doi: 10.1007/s11606-020-06345-5. Online ahead of print.
Is Lockdown Effective in Limiting SARS-CoV-2 Epidemic Progression?-a Cross-Country Comparative Evaluation Using Epidemiokinetic Tools


Bruno M?garbane[SUP] 1 2 [/SUP], Fanchon Bourasset[SUP] 3 4 [/SUP], Jean-Michel Scherrmann[SUP] 3 4 [/SUP]



Affiliations

Abstract

Background: To date, the risk/benefit balance of lockdown in controlling severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epidemic is controversial.
Objective: We aimed to investigate the effectiveness of lockdown on SARS-CoV-2 epidemic progression in nine different countries (New Zealand, France, Spain, Germany, the Netherlands, Italy, the UK, Sweden, and the USA).
Design: We conducted a cross-country comparative evaluation using a susceptible-infected-recovered (SIR)-based model completed with pharmacokinetic approaches.
Main measures: The rate of new daily SARS-CoV-2 cases in the nine countries was calculated from the World Health Organization's published data. Using a SIR-based model, we determined the infection (β) and recovery (γ) rate constants; their corresponding half-lives (t[SUB]1/2β[/SUB] and t[SUB]1/2γ[/SUB]); the basic reproduction numbers (R[SUB]0[/SUB] as β/γ); the rates of susceptible S(t), infected I(t), and recovered R(t) compartments; and the effectiveness of lockdown. Since this approach requires the epidemic termination to build the (I) compartment, we determined S(t) at an early epidemic stage using simple linear regressions.
Key results: In New Zealand, France, Spain, Germany, the Netherlands, Italy, and the UK, early-onset stay-at-home orders and restrictions followed by gradual deconfinement allowed rapid reduction in SARS-CoV-2-infected individuals (t[SUB]1/2β[/SUB] ≤ 14 days) with R[SUB]0[/SUB] ≤ 1.5 and rapid recovery (t[SUB]1/2γ[/SUB] ≤ 18 days). By contrast, in Sweden (no lockdown) and the USA (heterogeneous state-dependent lockdown followed by abrupt deconfinement scenarios), a prolonged plateau of SARS-CoV-2-infected individuals (terminal t[SUB]1/2β[/SUB] of 23 and 40 days, respectively) with elevated R[SUB]0[/SUB] (4.9 and 4.4, respectively) and non-ending recovery (terminal t[SUB]1/2γ[/SUB] of 112 and 179 days, respectively) was observed.
Conclusions: Early-onset lockdown with gradual deconfinement allowed shortening the SARS-CoV-2 epidemic and reducing contaminations. Lockdown should be considered as an effective public health intervention to halt epidemic progression.

Keywords: COVID-19; SARS-CoV-2; epidemic; lockdown; modeling; pharmacokinetics.
 
Back
Top Bottom